These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22868799)

  • 1. Instructions on laboratory monitoring in 200 drug labels.
    Geerts AF; De Koning FH; Van Solinge WW; De Smet PA; Egberts TC
    Clin Chem Lab Med; 2012 Feb; 50(8):1351-8. PubMed ID: 22868799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Instructions for monitoring clinical parameters in the Summary of Product Characteristics (SmPC) for psychotropic drugs: overview and applicability for clinical practice].
    Nederlof M; Stoker LJ; Egberts AC; Heerdink ER
    Tijdschr Psychiatr; 2016; 58(8):593-8. PubMed ID: 27527885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Instructions for clinical and biomarker monitoring in the Summary of Product Characteristics (SmPC) for psychotropic drugs: Overview and applicability in clinical practice.
    Nederlof M; Stoker LJ; Egberts TC; Heerdink ER
    J Psychopharmacol; 2015 Dec; 29(12):1248-54. PubMed ID: 26464457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of clarity of presentation and applicability of monitoring instructions for patients using lithium in clinical practice guidelines for treatment of bipolar disorder.
    Nederlof M; Kupka RW; Braam AM; Egberts A; Heerdink ER
    Bipolar Disord; 2018 Dec; 20(8):708-720. PubMed ID: 30105767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving patient understanding of prescription drug label instructions.
    Davis TC; Federman AD; Bass PF; Jackson RH; Middlebrooks M; Parker RM; Wolf MS
    J Gen Intern Med; 2009 Jan; 24(1):57-62. PubMed ID: 18979142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Information comparison of the effects of drugs on laboratory tests in drug labels and Young's book.
    Geerts AF; De Koning FH; Egberts TC; De Smet PA; Van Solinge WW
    Clin Chem Lab Med; 2012 Oct; 50(10):1765-8. PubMed ID: 23089706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To err is human: patient misinterpretations of prescription drug label instructions.
    Wolf MS; Davis TC; Shrank W; Rapp DN; Bass PF; Connor UM; Clayman M; Parker RM
    Patient Educ Couns; 2007 Aug; 67(3):293-300. PubMed ID: 17587533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are monitoring instructions provided in direct healthcare professional communications (DHPCs) of sufficient quality? A retrospective analysis of DHPCs sent out between 2007 and 2018.
    Højer MG; De Bruin ML; Boskovic A; Hallgreen CE
    BMJ Open; 2020 May; 10(5):e036498. PubMed ID: 32398337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The authors respond to "Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?".
    Degrassat-Théas A; Bocquet F; Sinègre M; Peigné J; Paubel P
    Health Policy; 2016 Aug; 120(8):892-3. PubMed ID: 27522451
    [No Abstract]   [Full Text] [Related]  

  • 10. Clarity and applicability of adverse drug reaction-related monitoring instructions in clinical practice guidelines for children and adolescents treated with antipsychotic drugs: a review of six clinical practice guidelines.
    Minjon L; Aarts JW; van den Ban E; Egberts TC; Heerdink ER
    BMJ Open; 2022 Mar; 12(3):e058940. PubMed ID: 35260462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety warnings and first aid instructions on consumer and pharmaceutical products in Nigeria: has there been an improvement?
    Nonyelum SC; Nkem N; Ifeyinwa CN; Orisakwe OE
    J Pak Med Assoc; 2010 Oct; 60(10):801-4. PubMed ID: 21381605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?
    Le Jeunne C; Billon N; Dandon A; ; Berdaï D; Adgibi Y; Bergmann JF; Bordet R; Carpentier A; Cohn E; Courcier S; Girault D; Goni S; Jolliet P; Liard F; Prot-Labarthe S; Simon T; Vernotte C; Westerloppe J
    Therapie; 2013; 68(4):225-39. PubMed ID: 23981260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
    Wang B; Canestaro WJ; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1938-44. PubMed ID: 25317785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quality of information on monitoring for haematological adverse drug reactions.
    Ferner RE; Coleman J; Pirmohamed M; Constable SA; Rouse A
    Br J Clin Pharmacol; 2005 Oct; 60(4):448-51. PubMed ID: 16187979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The variability and quality of medication container labels.
    Shrank WH; Agnew-Blais J; Choudhry NK; Wolf MS; Kesselheim AS; Avorn J; Shekelle P
    Arch Intern Med; 2007 Sep; 167(16):1760-5. PubMed ID: 17846395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of pictograms on medication labels for patients with limited literacy skills in a culturally diverse multiethnic population.
    Kheir N; Awaisu A; Radoui A; El Badawi A; Jean L; Dowse R
    Res Social Adm Pharm; 2014; 10(5):720-30. PubMed ID: 24355379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of potential drug-drug interactions in medical intensive care unit patients.
    Uijtendaal EV; van Harssel LL; Hugenholtz GW; Kuck EM; Zwart-van Rijkom JE; Cremer OL; Egberts TC
    Pharmacotherapy; 2014 Mar; 34(3):213-9. PubMed ID: 24390929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring and drugs of abuse testing on the cobas 6000 analyzer series: analytical performance under routine-like conditions.
    Brandhorst G; Luthe H; Domke I; Knoke C; Rhode KH; Sauter H; Oellerich M
    Clin Chem Lab Med; 2009; 47(7):854-9. PubMed ID: 19496737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs.
    Rougemont M; Ulrich S; Hiemke C; Corruble E; Baumann P
    Fundam Clin Pharmacol; 2010 Jun; 24(3):377-84. PubMed ID: 20199581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.